Takeda

We follow the science, to unlock innovation and pursue sustainable answers. We are guided by our commitment to patients, our people and the planet. Our vision is to deliver life-transforming treatments to those in need. We are steadfast in our purpose for better health for people and a brighter future for the world.

Come to Kyoto, Japan, to the 1,500-year-old Aio (hollyhock) Festival. Hollyhocks symbolize the connection to the gods. Climate change endangered the plant. Takeda’s Garden for Medicinal Plant Conservation stepped in to help. Watch the full 3-minute video to learn more: https://lnkd.in/e3tKZYyJ #Kyoto #Festival #OurStories

At our manufacturing site in Neuchâtel, Switzerland, we’ve launched a 18,000-square-meter photovoltaic installation, marking a major step forward on our journey to net-zero greenhouse gas emissions in our operations by 2035. But this project is about more than renewable energy. We’ve planted 630 shrubs, 45 trees, and 250 square meters of flowering meadows to support local biodiversity, with sheep lending a hand—or rather, a hoof—for natural mowing. With a total capacity of 3.6 MW and an annual output of 4 GWh, this installation is a significant addition to our renewable energy efforts. Even in autumn, it produced 5,000 kWh in a single day—enough to power an electric vehicle for a round trip from Neuchâtel to Beijing, China. Learn more about our net-zero roadmap in our 2024 annual integrated report (page 20): https://lnkd.in/e_bsNaYh #Sustainability #RenewableEnergy #Biodiversity #SolarPower #ClimateAction #ClimateChange

Living with narcolepsy type 1 (NT1) is a daily struggle marked by excessive daytime sleepiness, sudden loss of muscle tone, sleep paralysis, disrupted nighttime sleep, and hallucinations upon falling asleep or waking up. Learn more about NT1 and the orexin pathway by watching our 3-minute video.

Listen to Teresa Bitetti, President, Global Oncology, explain how our recent licensing agreement with Keros Therapeutics complements our R&D strategy by building on our legacy in Oncology. You can learn more in our R&D Day event recording, available here: https://lnkd.in/d8nSr_SZ For more information about forward-looking statements, please visit our website here: https://lnkd.in/eW9j_njW

As 2024 comes to a close, officially reported #dengue cases are set to surpass all previous records. There have been over 12 million cases worldwide this year—a 24-fold increase since 2000—making dengue the world’s fastest-growing mosquito-borne disease, now exacerbated by #climatechange. A year ago, at #COP28 in Dubai, with the world’s attention firmly on the accelerating impact of climate on health, nearly 30 global stakeholders came together to begin a transformative journey towards helping to reduce the burden of dengue. Now, we celebrate the anniversary of this meeting and the conception of the Collective Action on Dengue initiative, a unique collaboration that brings together experts from academia, industry, foundations, NGOs and more, dedicated to tackling the rising impact of dengue.  A group of organizations, including Asia Dengue Voice & Action (ADVA) Group, Duke-NUS Medical School, FIND, International Society For Neglected Tropical Diseases (ISNTD), International Society for Urban Health (ISUH), Malaria No More, MSD, Sabin Vaccine Institute,Vista Health Pte Ltd and World Mosquito Program (WMP) are working together to advance this initiative, laser focused on the Collective Action on Dengue's three strategic pillars—Urbanization, Innovation and Advocacy—to engage communities and contribute to building resilience against the spread of dengue. Keep an eye out for updates on the strides we're making towards tackling this public health threat— more exciting developments to come! 

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disease which affects the peripheral nervous system. Patients with CIDP can have symptoms such as muscle weakness, numbness, and loss of mobility. Learn more about #CIDP including how common it is and which age and sex it impacts most.

We are developing a GenAI tool with the goal of improving our regulatory submissions. We’re testing the tool’s prototype now, and so far, we’re seeing potential time-savings for our medical writers. That said, human oversight is central to the evolution of our tool. Read the story to learn about our approach and pilot results: https://lnkd.in/eTunmcFr #OurStories

India accounts for 17% of global maternal deaths and 26% of global neonatal deaths. A Takeda-funded project is tackling this challenge through innovative technology and patient care navigators. The result? Helping 20,000 pregnant women manage conditions such as pregnancy-induced hypertension, anemia and gestational diabetes. We’re proud to support this initiative in partnership with the non-profit organization Jhpiego to ensure healthier futures for women. Get the full story: https://lnkd.in/eVzhx5DU #OurStories

Hear Ramona Sequeira, President, Global Portfolio Division, speak about our commitment to addressing unmet patient needs as we advance our late-stage pipeline. The webcast recording of last week’s R&D Day event is available here: https://lnkd.in/d8nSr_SZ For more information about forward-looking statements, please visit our website here: https://lnkd.in/eSZyVw5j